Posted by Michael Wonder on 11 Dec 2025
Kymera Therapeutics announces US FDA fast track designation for KT-621, a first in class, oral STAT6 degrader for the treatment of atopic dermatitis
11 December 2025 - Fast track designation supported by positive results from the KT-621 BroADen Phase 1b atopic dermatitis patient trial.
Kymera Therapeutics today announced that the US FDA has granted fast track designation to KT-621, its first in class, oral STAT6 degrader, for the treatment of moderate to severe atopic dermatitis.
